GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Krystal Biotech Inc (FRA:4KB) » Definitions » PE Ratio (TTM)

Krystal Biotech (FRA:4KB) PE Ratio (TTM) : 108.13 (As of Dec. 12, 2024)


View and export this data going back to 2018. Start your Free Trial

What is Krystal Biotech PE Ratio (TTM)?

The PE Ratio (TTM), or Price-to-Earnings ratio, or P/E Ratio, is a financial ratio used to compare a company's market price to its Earnings per Share (Diluted). As of today (2024-12-12), Krystal Biotech's share price is €175.60. Krystal Biotech's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2024 was €1.62. Therefore, Krystal Biotech's PE Ratio (TTM) for today is 108.13.


The historical rank and industry rank for Krystal Biotech's PE Ratio (TTM) or its related term are showing as below:

FRA:4KB' s PE Ratio (TTM) Range Over the Past 10 Years
Min: 48.4   Med: 95.84   Max: 1977
Current: 105.55


During the past 8 years, the highest PE Ratio (TTM) of Krystal Biotech was 1977.00. The lowest was 48.40. And the median was 95.84.


FRA:4KB's PE Ratio (TTM) is ranked worse than
86.18% of 246 companies
in the Biotechnology industry
Industry Median: 27.425 vs FRA:4KB: 105.55

Krystal Biotech's Earnings per Share (Diluted) for the three months ended in Sep. 2024 was €0.82. Its Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2024 was €1.62.

As of today (2024-12-12), Krystal Biotech's share price is €175.60. Krystal Biotech's EPS without NRI for the trailing twelve months (TTM) ended in Sep. 2024 was €2.66. Therefore, Krystal Biotech's PE Ratio without NRI for today is 66.04.

During the past 8 years, Krystal Biotech's highest PE Ratio without NRI was 226.10. The lowest was 58.71. And the median was 190.11.

Krystal Biotech's EPS without NRI for the three months ended in Sep. 2024 was €1.16. Its EPS without NRI for the trailing twelve months (TTM) ended in Sep. 2024 was €2.66.

During the past 3 years, the average EPS without NRI Growth Rate was -10.10% per year. During the past 5 years, the average EPS without NRI Growth Rate was -28.80% per year.

During the past 8 years, Krystal Biotech's highest 3-Year average EPS without NRI Growth Rate was -4.90% per year. The lowest was -64.60% per year. And the median was -47.80% per year.

Krystal Biotech's EPS (Basic) for the three months ended in Sep. 2024 was €0.86. Its EPS (Basic) for the trailing twelve months (TTM) ended in Sep. 2024 was €1.68.


Krystal Biotech PE Ratio (TTM) Historical Data

The historical data trend for Krystal Biotech's PE Ratio (TTM) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Krystal Biotech PE Ratio (TTM) Chart

Krystal Biotech Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
PE Ratio (TTM)
Get a 7-Day Free Trial At Loss At Loss At Loss At Loss 318.10

Krystal Biotech Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
PE Ratio (TTM) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only At Loss 318.10 94.64 50.17 102.26

Competitive Comparison of Krystal Biotech's PE Ratio (TTM)

For the Biotechnology subindustry, Krystal Biotech's PE Ratio (TTM), along with its competitors' market caps and PE Ratio (TTM) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Krystal Biotech's PE Ratio (TTM) Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Krystal Biotech's PE Ratio (TTM) distribution charts can be found below:

* The bar in red indicates where Krystal Biotech's PE Ratio (TTM) falls into.



Krystal Biotech PE Ratio (TTM) Calculation

The PE Ratio (TTM), or Price-to-Earnings ratio, or P/E Ratio, is a financial ratio used to compare a company's market price to its Earnings per Share (Diluted). It is the most widely used ratio in the valuation of stocks.

Krystal Biotech's PE Ratio (TTM) for today is calculated as

PE Ratio (TTM)=Share Price/Earnings per Share (Diluted) (TTM)
=175.60/1.624
=108.13

Krystal Biotech's Share Price of today is €175.60.
Krystal Biotech's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €1.62.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

PE Ratio (TTM)=Market Cap /Net Income

There are at least three kinds of PE Ratio (TTM)s used by different investors. They are Trailing Twelve Month PE Ratio (TTM) or PE Ratio (TTM) (TTM), Forward PE Ratio, or PE Ratio without NRI. A new PE Ratio (TTM) based on inflation-adjusted normalized PE Ratio (TTM) is called Shiller PE Ratio, after Yale professor Robert Shiller.

In the calculation of PE Ratio (TTM), the earnings per share used are the earnings per share over the past 12 months. For Forward PE Ratio, the earnings are the expected earnings for the next twelve months. In the case of PE Ratio without NRI, the reported earnings less the non-recurring items are used.

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. Since it looks at the average over the last 10 years, Shiller PE Ratio is also called PE10.


Krystal Biotech  (FRA:4KB) PE Ratio (TTM) Explanation

The PE Ratio (TTM) can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. For example, if a company earns $2 a share per year, and the stock is traded at $30, the PE Ratio (TTM) is 15. Therefore it takes 15 years for the company to earn back the $30 you paid for its stock, assuming the earnings stays constant over the next 15 years.

In real business, earnings never stay constant. If a company can grow its earnings, it takes fewer years for the company to earn back the price you pay for the stock. If a company's earnings decline it takes more years. As a shareholder, you want the company to earn back the price you pay as soon as possible. Therefore, lower P/E stocks are more attractive than higher P/E stocks so long as the PE Ratio (TTM) is positive. Also for stocks with the same PE Ratio (TTM), the one with faster growth business is more attractive.

If a company loses money, the PE Ratio (TTM) becomes meaningless.

To compare stocks with different growth rates, Peter Lynch invented a ratio called PEG Ratio. PEG Ratio is defined as the PE Ratio (TTM) divided by the growth ratio. He thinks a company with a PE Ratio (TTM) equal to its growth rate is fairly valued. Still he said he would rather buy a company growing 20% a year with a PE Ratio (TTM) of 20, instead of a company growing 10% a year with a PE Ratio (TTM) of 10.

Because the PE Ratio (TTM) measures how long it takes to earn back the price you pay, the PE Ratio (TTM) can be applied to the stocks across different industries. That is why it is the one of the most important and widely used indicators for the valuation of stocks.

Similar to the PE Ratio without NRI or PS Ratio or Price-to-Operating-Cash-Flow or Price-to-Free-Cash-Flow , the PE Ratio (TTM) measures the valuation based on the earning power of the company. This is where it is different from the PB Ratio , which measures the valuation based on the company's balance sheet.


Be Aware

Investors need to be aware that the PE Ratio (TTM) can be misleading a lot of times, especially when the underlying business is cyclical and unpredictable. As Peter Lynch pointed out, cyclical businesses have higher profit margins at the peaks of the business cycles. Their earnings are high and PE Ratio (TTM)s are artificially low. It is usually a bad idea to buy a cyclical business when the PE Ratio (TTM) is low. A better ratio to identify the time to buy a cyclical businesses is the PS Ratio .

PE Ratio (TTM) can also be affected by non-recurring-items such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than PE Ratio (TTM).


Krystal Biotech PE Ratio (TTM) Related Terms

Thank you for viewing the detailed overview of Krystal Biotech's PE Ratio (TTM) provided by GuruFocus.com. Please click on the following links to see related term pages.


Krystal Biotech Business Description

Traded in Other Exchanges
Address
2100 Wharton Street, Suite 701, Pittsburgh, PA, USA, 15203
Krystal Biotech Inc is engaged in the healthcare sector in the United States. It is focused on the development of easy-to-use, redosable gene therapies to improve the lives of patients living with debilitating diseases. The company used its proprietary gene therapy platform, STAR-D to develop treatments for rare or orphan dermatological indications caused by the absence of or a mutation in a single gene. It plans to leverage its platform to expand its pipeline to include other dermatological indications in the future. The company has one operating segment, which is the business of developing and commercializing pharmaceutical products.

Krystal Biotech Headlines

No Headlines